Detection of HPV E6 oncoprotein from urine via a novel immunochromatographic assay
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
De Oliveira, C.M, et al. Detection of Hpv E6 Oncoprotein From Urine Via a Novel Immunochromatographic Assay. Public Library of Science, 2020. https://doi.org/10.17615/15y4-ed88APA
De Oliveira, C., Musselwhite, L., De Paula Pantano, N., Vazquez, F., Smith, J., Schweizer, J., Belmares, M., Possati Resende, J., De Andrade Vieira, M., Longatto Filho, A., & Guerreiro Fregnani, J. (2020). Detection of HPV E6 oncoprotein from urine via a novel immunochromatographic assay. Public Library of Science. https://doi.org/10.17615/15y4-ed88Chicago
De Oliveira, C.M., L.W Musselwhite, N De Paula Pantano, F.L Vazquez, J.S Smith, J Schweizer, M Belmares et al. 2020. Detection of Hpv E6 Oncoprotein From Urine Via a Novel Immunochromatographic Assay. Public Library of Science. https://doi.org/10.17615/15y4-ed88- Creator
-
de Oliveira, C.M.
- Other Affiliation: Molecular Oncology Research Center-Barretos Cancer Hospital
-
Musselwhite, L.W.
- Other Affiliation: Duke University
-
de Paula Pantano, N.
- Other Affiliation: Barretos Cancer Hospital
-
Vazquez, F.L.
- Other Affiliation: Barretos Cancer Hospital
-
Smith, J.S.
- Affiliation: Gillings School of Global Public Health
-
Schweizer, J.
- Other Affiliation: Arbor Vita Corporation
-
Belmares, M.
- Other Affiliation: Arbor Vita Corporation
-
Possati-Resende, J.C.
- Other Affiliation: Prevention Department-Barretos Cancer Hospital
-
de Andrade Vieira, M.
- Other Affiliation: Barretos Cancer Hospital
-
Longatto-Filho, A.
- Other Affiliation: University of São Paulo
-
Guerreiro Fregnani, J.H.T.
- Other Affiliation: A.C. Camargo Cancer Center
- Abstract
- Cervical cancer is a significant public health problem, especially in low- and middle-income countries, where women have little access to cervical cancer screening; consequently 80% of cervical cancer related mortality occurs in these regions. The development of screening methods that need less infrastructure thus represents an urgent medical need. The study aims to compare the detection rates of high-risk human papillomavirus 16 and 18 E6 oncoprotein in urine, vaginal self-collected, and cervical scrapes of women using the OncoE6™ Cervical Test and compare the HPV16 and/or HPV18 E6 detection rates with the HPV DNA testing. Paired urine, vaginal self-collected and cervical specimens were collected from 124 women who participated in cervical cancer screening or treatment in this proof-of-concept study and underwent to HPV16/18-E6 testing and high-risk HPV DNA testing prior to treatment of cervical neoplasia or cancer. Concordance between urinary, vaginal and cervical HPV16/18-E6 and HPV-DNA testing was evaluated for patients classified as negative group (<CIN2) and histological positive group (CIN2, CIN3 and invasive carcinoma). Overall, HPV16/18-E6 oncoprotein was detected in 30.6% of cervical samples, 20.3% of self-collected vaginal samples and 21% of urine samples. Regarding the clinical sensitivity, the HPV16/18-E6 oncoprotein was not detected in CIN2 cases, and was detected at low rates in CIN3 cases. The clinical sensitivity of the HPV16/18-E6 oncoprotein for detecting invasive cervical cancer was 70% for cervical scrapes, 55% for self-collected vaginal samples and 52% for urine samples. This study reports the urinary detection of E6 oncoprotein in vivo for the first time and our results suggest that this detection is only for invasive/microinvasive lesions. Then, further protocol development and standardization to achieve a clinical sensitivity for CIN2/3 detection close to what can be achieved for invasive lesions using the physician collected cervical is needed.
- Date of publication
- 2020
- Keyword
- diagnostic test accuracy study
- uterine cervix tumor
- immunoassay
- uterine cervix carcinoma in situ
- protein analysis
- Repressor Proteins
- repressor protein
- diagnostic accuracy
- human tissue
- Human papillomavirus 16
- sensitivity and specificity
- Female
- Middle Aged
- controlled study
- virology
- Human papillomavirus type 16
- genetics
- Vagina
- immunoaffinity chromatography
- oncoprotein
- Oncogene Proteins, Viral
- uterine cervix carcinoma
- urine
- papillomavirus infection
- E6 protein, Human papillomavirus type 16
- Adult
- major clinical study
- Uterine Cervical Neoplasms
- uterine cervix cancer
- vagina
- procedures
- in vivo study
- human
- middle aged
- urine sampling
- Human papillomavirus DNA test
- DNA-Binding Proteins
- histopathology
- cancer screening
- female
- standardization
- Human papillomavirus type 18
- Article
- DNA binding protein
- point of care testing
- adult
- Immunoassay
- Humans
- comparative study
- proof of concept
- protein E6
- nonhuman
- Papillomavirus Infections
- Human Papillomavirus DNA Tests
- E6 protein, Human papillomavirus type 18
- DOI
- Identifier
- Resource type
- Article
- License
- Attribution 4.0 International
- Journal title
- PLoS ONE
- Journal volume
- 15
- Journal issue
- 4
- Language
- English
- Version
- Publisher
- Funder
- Hospital de Câncer de Barretos, BCH
- Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP: 2016/19527-7
- Bill and Melinda Gates Foundation, BMGF: OPP1151345
- ISSN
- 1932-6203
- Publisher
- Public Library of Science
Relations
- Parents:
- In Collection:
This work has no parents.